News: Press Releases

Fougera Announces The First Approval Of Ciclopirox Olamine Cream USP (Rx)

Melville, New York - December 29, 2004 - Today, Fougera the specialty pharmaceutical manufacturer announced it received first approval from the FDA for Ciclopirox Cream 0.77% (Rx). This product is AB rated to Loprox® Cream by Medicis® and is available in 15g, 30g and 90g tubes. (See product package insert for full prescribing information.)

David Klaum, Vice President of Sales and Marketing stated,
"After recently receiving first approval for Ciclopirox Topical Suspension USP, we are excited to add this important additional first approval and first-to-market to the Ciclopirox line of products, providing the market with another quality option for their topical needs."

As a specialty pharmaceutical manufacturer of topical steroids, antibiotics and antifungal products, as well as ophthalmics, Fougera has received more topical generic FDA approvals than any other company during the past six years. This ability to provide a continuing stream of new products benefits both health care providers seeking multi-source alternatives with the ability to reduce health care costs, and patients whose conditions warrant their application.

For more information on Fougera’s complete line of topicals, or any other quality Fougera products, please call Fougera Customer Service at (800) 645-9833. Or visit the company online at www.fougera.com.

Fougera is a leading manufacturer and distributor of a wide range of multi-source topical and ophthalmic pharmaceuticals, in both prescription and over-the-counter dosage forms.